Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Innsbruck – page 9

363 clinical trials in Innsbruck, Austria across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Innsbruck at a glance
363
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

363 trials in Innsbruck

Open in trial search

Study on the Effects of Alpha-1 Antitrypsin and Prednisolone in Patients with Severe Alcohol-Related Hepatitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Medizinische Universitaet Innsbruck

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Study on Protamine Sulfate for Reducing Bleeding and Ischemic Events in Adults with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Protamine Sulfate
  • Sponsor:Klinikum Der Universitat Munchen AöR

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab and Upadacitinib in Adults with Moderate to Severe Crohn's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham

Meningioma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Neoplasm malignant+1

Recruiting

Study on the Diagnostic Performance of 68Ga-ABS011 PET/CT for Patients with Metastatic Breast Cancer

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:68Ga-Nota-Abscint-Her2
  • Sponsor:Abscint

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Innsbruck

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on innovative treatments for various cancers, including bladder cancer, breast cancer, and gastric cancer. Studies evaluate novel combination therapies and targeted treatments to improve patient outcomes.

  • Non-muscle invasive bladder cancer treatment
  • HER2-positive cancer therapies
  • Glioblastoma management

Research emphasizes personalized medicine approaches and innovative drug combinations.

02 Neurological Disorders

Groundbreaking studies examining treatments for multiple sclerosis and other neurological conditions. Research focuses on testing new therapeutic agents and evaluating their effectiveness in managing disease progression.

  • Multiple sclerosis treatment innovations
  • Brain structure and function studies
  • Neurological response assessment

Trials aim to advance understanding of disease mechanisms and improve treatment outcomes.

03 Inflammatory Conditions

Clinical investigations into chronic inflammatory diseases, including Crohn's Disease and ulcerative colitis. Studies evaluate novel therapeutic approaches and combination treatments.

  • Gastrointestinal inflammation management
  • Chronic rhinosinusitis treatment
  • Inflammatory response modulation

Research focuses on improving quality of life for patients with chronic inflammatory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.